Reduced levels of lysyl oxidase in plasma extracellular vesicles: a potential biomarker associated with the risk of brain metastases in lung adenocarcinoma - Summary - MDSpire

Reduced levels of lysyl oxidase in plasma extracellular vesicles: a potential biomarker associated with the risk of brain metastases in lung adenocarcinoma

  • By

  • Jing Li

  • Yu Pei

  • Jia-Li Sun

  • Fen Hu

  • Han-Xue Yang

  • Jun Zhou

  • Cong-Ting Wu

  • Xingjie Hao

  • Wei Gong

  • Yang Yao

  • Yi Liu

  • March 12, 2026

  • 0 min

Share

Objective:

To identify plasma exosomal biomarkers associated with brain metastases in lung adenocarcinoma (LUAD) and elucidate their molecular mechanisms.

Key Findings:
  • Lysyl oxidase (LOX) levels were significantly reduced in plasma EVs from patients with brain metastases compared to those without.
  • The study identified specific proteins in EVs that may serve as biomarkers for predicting brain metastases in LUAD.
Interpretation:

The findings suggest that plasma exosomal proteins, particularly LOX, could be utilized as non-invasive biomarkers for early detection of brain metastases in LUAD patients.

Limitations:
  • The study's cohort was limited to patients with stage IV LUAD, which may not generalize to earlier stages.
  • Further validation in larger, diverse populations is needed to confirm the findings.
Conclusion:

This research highlights the potential of plasma exosomal biomarkers in monitoring high-risk LUAD populations for brain metastases, paving the way for future EV-targeted therapies.

Original Source(s)

Reduced levels of lysyl oxidase in plasma extracellular vesicles: a potential biomarker associated with the risk of brain metastases in lung adenocarcinoma

  • by Jing Li, Yu Pei, Jia-Li Sun, Fen Hu, Han-Xue Yang, Jun Zhou, Cong-Ting Wu, Xingjie Hao, Wei Gong, Yang Yao, Yi Liu

  • March 12, 2026

Related Content

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Understanding cardiac toxicity and immune responses to thoracic radiation therapy in non-small cell lung cancer – implications for future research

An ASCO preview: What to watch for at cancer research’s big meeting